Fused Benzoisoxazolyl Compounds as KAT6A Inhibitors

Fri, 17 Apr 2026 23:23:51 +0000
Intellectual Property

The European Patent Office published patent application EP4448109A1 for fused benzoisoxazolyl compounds as KAT6A inhibitors, filed jointly by Aurigene Oncology Limited and Olema Pharmaceuticals, Inc. The invention covers heterocyclic antineoplastic compounds classified under A61P 35/00 and C07D 498/04. The patent is designated for all European Patent Convention contracting states.